CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has sold its rights to future royalties in Lexiva ® and Agenerase ® under its 1993 ...

[email protected] or Michael Partridge of Vertex Pharmaceuticals, Incorporated, 617-577-6108 [email protected] ...

Vertex brought in just over $34 million in royalty revenue from GSK in 2007 for its HIV treatments. The investment entity that purchased the future royalty stream declined to be identified.

Biotech firm Vertex Pharmaceuticals Inc. agreed to buy Aurora Biosciences Corp. for about $592 million in stock to gain tools and systems used to search for drug candidates.

One with no "docking station" poses an even bigger problem. Vertex has one drug already on the market for HIV, also a protease inhibitor called Agenerase, which received FDA approval in 1999.

Vertex Pharmaceuticals Inc<VRTX.O> said on Tuesday it sold the rights to future royalties on two HIV drugs under a license agreement with GlaxoSmithKline <GSK.L> to unnamed financial ...

Vertex Pharmaceuticals , a small biotech shop, has produced only one drug in 12 years of existence: Agenerase, an also-ran AIDS drug with $80 million in sales (the leader is near $400 million).The ...

Vertex Throws Its Weight At Hep C Jun 05, 2008, 02:05pm EDTJun 19, 2013, 04:50pm EDT ...

Vertex Pharmaceuticals has priced a public offering of 9.1 million shares at $33, hoping to raise slightly more than $300 million in the process. The new terms include an additional 1.1 million ...